设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 633|回复: 0

CD123 AML通过靶向嵌合抗原受体,一种新的灵丹妙药AML疗法

[复制链接]
发表于 2015-8-27 10:40:39 | 显示全部楼层 |阅读模式
CD123 AML targeting by chimeric antigen
ReceptorsA novel magic bullet for AML therapeutics?
CD123 AML通过靶向嵌合抗原受体,一种新的灵丹妙药AML疗法?
Abstract:
Chimeric antigenreceptor (CAR) modified cells have emerged as powerful tools for controllingleukemias.  we recently showed thatanti-CD123 CAR-expressing cytokine-induced killer t cell treatment is aneffective immunotherapeutic approach to eradicate Acute Myeloid Leukemia (AML)cells. here, we discuss how this genetically modifiedcell-based strategy could be relevant to the field of AML therapeutics.
摘要:
嵌合抗原受体(CAR)的改进型的T细胞已成为控制白血病强大的工具。我们最近发现,抗CD123 CAR表达的细胞因子诱导的杀伤T细胞治疗是消除急性髓系白血病(AML)细胞的有效免疫治疗的方法。

CD123 AML targeting by chimeric antigen receptor.pdf

666.2 KB, 下载次数: 294

您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-4-28 11:00 , Processed in 0.111907 second(s), 27 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表